Atopic Dermatitis CD19+ B Cells

About Atopic Dermatitis CD19+ B Cells

Atopic Dermatitis CD19+ B Cells for Allergy and IgE Research

Atopic Dermatitis CD19+ B Cells are cryopreserved from peripheral blood of IRB-consented adult donors diagnosed with atopic dermatitis. These CD19+ B cells reflect disease-associated humoral alterations and are a direct resource for studying IgE class switching, B cell activation, and allergic immunity.

Why B Cells Matter in Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory skin disease driven by epidermal barrier dysfunction and type 2 (Th2) immune skewing — not autoimmunity. B cells sit at a decisive point in that pathway, because they are where IgE actually comes from:

• IgE class switching — IL-4 and IL-13 drive B cells to switch to IgE production, the defining humoral event in atopy and the mechanism upstream of mast cell and basophil sensitisation
• Elevated total and allergen-specific IgE, correlating with disease severity in the extrinsic (allergic) phenotype
• Expanded IgE-committed and memory B cell populations
• Reduced regulatory B cell function — diminished IL-10-producing Bregs, weakening a restraining signal on type 2 inflammation
• Local skin B cell involvement and antigen presentation supporting Th2 responses
• Treatment effects — dupilumab blocks IL-4Rα signalling and measurably reduces IgE over time, so treatment status is essential context

Note that AD divides into extrinsic (IgE-high, allergen-sensitised) and intrinsic (IgE-normal) phenotypes, and these behave differently in B cell studies — worth specifying up front.

Donor Stratification Available

• Total and allergen-specific IgE where tested, with titre values
• Phenotype — extrinsic (IgE-high) vs intrinsic (IgE-normal)
• Disease severity — EASI, SCORAD, or IGA scores where recorded
• Atopic comorbidities — asthma, allergic rhinitis, food allergy
• Treatment status — topical-only, or on dupilumab, JAK inhibitor, or systemic immunosuppressant
• Matched non-atopic controls with low total IgE available

Product Features

• Research Use Only (RUO), CD19+ enriched B cells
• Isolated from clinically diagnosed atopic dermatitis donors
• High viability and enrichment
• Cryopreserved in CryoStor® CS10 media
• Processed within 24 hours of collection
• Flow cytometry purity and viability data per lot
• Ethically sourced with IRB approval and HIPAA compliance

De-identified Donor Data

• Confirmed diagnosis of atopic dermatitis
• Demographics: age, sex assigned at birth, race/ethnicity
• Self-reported clinical history and medication use

Applications

• IgE class switching and germline transcription studies
• B cell phenotyping and function in atopic dermatitis
• IgE production and BCR signalling assays
• Regulatory B cell (Breg) and IL-10 function studies
• BCR repertoire sequencing
• Anti-IgE and IL-4Rα therapeutic mechanism research
• Disease mechanism studies and biomarker identification
• Preclinical immunotherapy development

Other Atopic Dermatitis Specimen Types

Matched material is available as AD CD56+ NK cells, PBMC, serum, plasma, and skin punch biopsy for lesional tissue. Related atopic cohorts include allergy serum and chronic spontaneous urticaria.

Compliance and Quality Assurance

• IRB-approved collection and 21 CFR Part 11-compliant e-consent
• Standardized processing and quality protocols
• HIPAA-compliant data handling

Ordering & Customization

Atopic Dermatitis CD19+ B Cells are offered in standard or custom aliquot sizes. For pricing, regulatory documentation, or international support, contact learnmore@sanguinebio.com. For the full range, see our human CD19+ B cells collection.